Menu
Close
Global
×

Company News

Home Company News News detail
ImmuneOnco Biopharmaceuticals' IMM2520 project completes first subject dosing
2023-03-23
1557
Previous article：ImmuneOnco Biopharmaceuticals IMM47, IMM2520 and IMM2510 invention patents were granted by the State Intellectual Property Office of China
Next article：ImmuneOnco Biopharmaceuticals' IMM47, IMM40H, IMM2520, and IMM2902 projects debut at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Back
Hot recommendation
2026-10-15
ImmuneOnco Subsidiary ImmuneCare's IND Application for IMC-003 in Pulmonary Hypertension Associated with Left Heart Disease Accepted by China's CDE
More
2026-10-10
ImmuneOnco to Present Latest Phase Ib/II Clinical Results of IMM0306 in Systemic Lupus Erythematosus at ACR 2026
More
2026-09-23
ImmuneOnco Reports Breakthrough Phase II Data for IMM0306 in Combination with Lenalidomide: ORR of 92.3% in R/R MZL and 88.6% in R/R FL, Demonstrating a Compelling Efficacy and Safety Profile
More

For more information

Please follow the official wechat public account